PBYI stock forecast
Our latest prediction for Puma Biotechnology, Inc.'s stock price was made on the June 12, 2017 when the stock price was at 79.20$.
In the short term (2weeks), PBYI's stock price should underperform the market by -2.47%. During that period the price should oscillate between -11.99% and +18.92%.
In the medium term (3months), PBYI's stock price should underperform the market by -1.38%. During that period the price should oscillate between -25.95% and +46.94%.Get email alerts
About Puma Biotechnology, Inc.
Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
At the moment the company generates 280M USD in revenues.
On its last earning announcement, the company reported a loss of -2.47$ per share.
The book value per share is 1.01$
Three months stock forecastJune 12, 2017
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|